Real-World Study Highlights Adverse Events Associated with Lenvatinib Use

A recent study focused on the real-world adverse events (AEs) associated with lenvatinib, a medication used in cancer treatment, has shed light on its safety profile. The research, spanning from the first quarter of 2015 to the fourth quarter of 2023, utilized data mining techniques to analyze and quantify lenvatinib-associated AEs, identifying 68 Preferred Terms (PTs) with significant imbalances.

Among the findings, unexpected AEs such as immune-mediated hepatitis, portal vein thrombosis, and adrenal insufficiency were linked to lenvatinib use. Notably, the study revealed that lenvatinib alone had a stronger association with adrenal insufficiency compared to its use in combination with pembrolizumab. Additionally, hepatic encephalopathy showed a stronger correlation with drug use in male patients with hepatocellular carcinoma.

The study also highlighted that most AEs occurred during the first month after the initiation of treatment, with a median onset time of 41 days. Furthermore, potential targets of lenvatinib, including FGFR4, PDGFRA, and KIT, were identified as potentially linked to the development of cholecystitis, cholangitis, and hepatic encephalopathy.

This research underscores the importance of monitoring and managing AEs in patients undergoing lenvatinib treatment, providing valuable insights for healthcare professionals in optimizing patient care and safety.